PMCB
PharmaCyte Biotech, Inc.0.9500
+0.0081+0.86%
Dec 16, 4:00:01 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
No earnings call transcript available
Key Stats
Market Cap
6.46MP/E (TTM)
15.83Basic EPS (TTM)
0.06Dividend Yield
0%Recent Filings
10-Q
Q3 FY2026 results
PharmaCyte Biotech posted a Q3 operating loss of $2.1M, up from $0.96M y/y, driven by higher G&A from RSU grants and capital raise costs, while R&D dipped to $93K. Net swung to a $0.7M profit from fair value gains on warrant liabilities ($1.9M) and QCLS investments ($1.7M), yet preferred dividends and accretion yielded a $1.6M common loss at $(0.17) per share on 9.3M diluted shares—anti-dilution flagged. Cash climbed to $20.2M from Series C proceeds ($6.3M net) and Femasys note repayment ($5M), funding ops for 12+ months despite no revenue. Warrant liabilities hit $13.7M; Nasdaq bid price noncompliance looms. Cash cushions the stall.
10-Q
Q2 FY2026 results
PharmaCyte Biotech posted a Q2 FY2026 operating loss of $1.4M, up 24% y/y from $1.1M, driven by higher R&D costs at $141K while G&A rose 22% to $1.2M. Net loss exploded to $7.4M from $1.5M, as warrant liability fair value changes swung $10.5M negative versus $1.8M positive, dwarfing $206K interest income and QCLS investment gains. Cash held steady at $15.4M after $7M Series C preferred raise offset $3M QCLS investment and $3M operating burn; no debt, FCF not disclosed in the 10-Q. FDA clinical hold persists on LAPC IND. Nasdaq bid price noncompliance looms.
8-K
Nasdaq bid price deficiency notice
8-K
Stockholders boost equity plan
PharmaCyte Biotech stockholders approved amending the 2022 Equity Incentive Plan on October 30, 2025, adding 2,250,000 shares to the pool, bringing the total to 5,000,000. This bolsters talent retention amid Nasdaq compliance for prior convertible preferred stock and warrants. Plan now supports more options. Yet dilution looms for common holders.
10-Q
Q1 FY2026 results
PharmaCyte Biotech posted a Q1 FY2026 operating loss of $848K, down 33% y/y from $1.27M as G&A expenses dropped sharply while R&D held steady near $95K; yet net loss exploded to $8.36M or $(1.23) per share from $23.4M profit last year, driven by $7.7M fair-value hits on TNF and Femasys investments. Cash burned $2.0M to $13.2M, ample runway past twelve months bolstered by $7M Series C raise in August 2025. No revenue, no debt. FDA clinical hold on LAPC IND persists.
AURX
Nuo Therapeutics, Inc.
2.00-0.15
CARM
Carisma Therapeutics, Inc.
0.05+0.00
CBIO
Crescent Biopharma, Inc.
12.92-0.29
CMMB
Chemomab Therapeutics Ltd.
2.06+0.00
CNBX
CNBX Pharmaceuticals Inc.
0.00+0.00
MAIA
MAIA Biotechnology, Inc.
1.23-0.12
NWBO
Northwest Biotherapeutics, Inc.
0.25+0.01
PPCB
Propanc Biopharma, Inc.
0.73-0.03
PSTV
PLUS THERAPEUTICS, Inc.
0.64+0.01
RNXT
RenovoRx, Inc.
0.84-0.10